Rebamipide, beyond concentrations of 106 M to 104 M, is known to inhibit the cytotoxicity of neutrophils and to suppress the neutrophil function stimulated by Helicobacter pylori (14, 15). These effects of rebamipide are thought to protect against the gastric mucosal inflammation associated with Helicobacterpylori. Arakawa et al have reported that rebamipide decreases the recurrence of gastric ulcers withoutaffecting Helicobacter pylori status and that it is almost equal to amoxicillin in reducing the recurrence of ulcers when administered with omeprazole (16).Eradication therapy against Helicobacter pylori is mosteffective in preventing the recurrence of gastric ulcers, but if patients cannot be cured of Helicobacter pylori infection for any reason, rebamipide might be useful in preventing the recurrence of gastric ulcer.